ESMO Open published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.
Review the original article for the full source wording and details.